{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-092272","form_type":"8-K","ticker":"KYMR","cik":"0001815442","company_name":"Kymera Therapeutics, Inc.","filed_at":"2024-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.629701+00:00","generated_at":"2026-05-31T11:51:44.090876+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Kymera Q2 net loss $42.1M, cash $702M; Sanofi expands KT-474 Phase 2","bullets":["Net loss $42.1M in Q2 2024 vs $38.8M in Q2 2023; revenue from Sanofi collaboration $25.7M.","Cash & equivalents $702M as of June 30, 2024; projected runway into first half 2027.","Sanofi plans to expand KT-474 (IRAK4) Phase 2 trials in HS and AD after interim safety/efficacy review.","STAT6 degrader KT-621 Phase 1 on track for H2 2024; TYK2 degrader KT-294 Phase 1 in H1 2025.","KT-253 (MDM2) and KT-333 (STAT3) Phase 1a enrollment completion expected H2 2024 with data presentations."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-092272","json":"https://secwatch.observer/filing/0000950170-24-092272.json","markdown":"https://secwatch.observer/filing/0000950170-24-092272.md","text":"https://secwatch.observer/filing/0000950170-24-092272.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1815442/000095017024092272/0000950170-24-092272-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1815442/000095017024092272/kymr-20240807.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T11:51:44.090876+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}